Cargando…
Imaging Properties and Tumor Targeting of (68)Ga-NeoBOMB1, a Gastrin-Releasing Peptide Receptor Antagonist, in GIST Patients
Background: Gastrin-releasing peptide receptors (GRPRs) are molecular imaging targets in multiple malignancies. Recently, NeoBOMB1, a (68)Ga-labelled antagonist to GRPRs, was developed for PET. Here we report the outcome of a Phase I/IIa clinical trial (EudraCT 2016-002053-38) describing diagnostic...
Autores principales: | Gruber, Leonhard, Decristoforo, Clemens, Uprimny, Christian, Hohenberger, Peter, Schoenberg, Stefan O., Orlandi, Francesca, Mariani, Maurizio Franco, Manzl, Claudia, Kasseroler, Maria Theresia, Tilg, Herbert, Zelger, Bettina, Jaschke, Werner R., Virgolini, Irene J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9687401/ https://www.ncbi.nlm.nih.gov/pubmed/36428467 http://dx.doi.org/10.3390/biomedicines10112899 |
Ejemplares similares
-
NeoBOMB1, a GRPR-Antagonist for Breast Cancer Theragnostics: First Results of a Preclinical Study with [(67)Ga]NeoBOMB1 in T-47D Cells and Tumor-Bearing Mice
por: Kaloudi, Aikaterini, et al.
Publicado: (2017) -
Radiopharmaceutical Formulation and Preclinical Testing of (68)Ga-Labeled DOTA-MGS5 for the Regulatory Approval of a First Exploratory Clinical Trial
por: Hörmann, Anton A., et al.
Publicado: (2021) -
Current status of theranostics in prostate cancer
por: Virgolini, Irene, et al.
Publicado: (2017) -
Comparison of Early Imaging and Imaging 60 min Post-Injection after Forced Diuresis with Furosemide in the Assessment of Local Recurrence in Prostate Cancer Patients with Biochemical Recurrence Referred for 68Ga-PSMA-11 PET/CT
por: Bayerschmidt, Steffen, et al.
Publicado: (2021) -
Enhancing Clinical Diagnosis for Patients With Persistent Pulmonary Abnormalities After COVID-19 Infection: The Potential Benefit of (68)Ga-FAPI PET/CT
por: Sviridenko, Anna, et al.
Publicado: (2022)